EC
DYN icon

EntryPoint Capital’s Dyne Therapeutics DYN Stock Holding History

EntryPoint Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,479
Closed -$87.5K – 757
2024
Q2 		$87.5K Sell
2,479
-5,073
-67% -$147K 0.13% 365
2024
Q1 		$214K Buy
+7,552
New +$171K 0.19% 97

Other funds holding DYN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EntryPoint Capital's DYN Position: Q3 2024 in Review

EntryPoint Capital sold out of Dyne Therapeutics (DYN) in Q3 2024, closing a stake of 2,479 shares — an estimated $87.5K sold.

EntryPoint Capital first reported a position in DYN in Q1 2024 and held it in 2 quarters. The position peaked at $214K in Q1 2024. 200 funds tracked by Wall St. Rank hold DYN as of Q3 2024.

  • EntryPoint Capital reported no remaining Dyne Therapeutics position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 2,479 Dyne Therapeutics shares in Q3 2024, an estimated $87.5K.
  • EntryPoint Capital first reported a position in Dyne Therapeutics in Q1 2024 and held it in 2 quarters.
  • EntryPoint Capital's Dyne Therapeutics position peaked at $214K in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.